Genprex

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of the micro-cap gene therapy company Genprex Inc (NASDAQ: GNPX) were advancing strongly on above-average volume Tuesday.

Why Are Shares Of Gene Therapy Company Genprex Are Surging Higher

Shares of Genprex Inc. GNPX, +56.61% climbed 53% in morning trading on Wednesday after the company said the Food and Drug Administration had granted its experimental cancer treatment a fast-track designation.

Genprex's stock rallies on FDA fast-track designation

Shares of thinly-traded gene therapy company Genprex Inc (NASDAQ: GNPX) are soaring on more than 50 times their average volume Tuesday.

Penny Stock Rips 260% Higher On Fast Track Designation For Experimental Lung Cancer Gene Therapy

When companies see their shares rise by 100% or more in a single day, it’s usually because of a buyout or an extremely positive change in a company’s future prospects.

FDA Fast Track on Lung Cancer Treatment Brings Exponential Gains for This Microcap Stock

NEW YORK, Sept.  26, 2019  (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers.”

Genprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer Treatment

NEW YORK, Sept.  25, 2019  (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.

Genprex (GNPX) Featured in Publication on Advances in Potential Breast Cancer Treatments

NEW YORK, Sept.  06, 2019  (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled “Gene Therapy Treatments Offer Hope for Cancer Patients.”

Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Lung Cancer and Gene Therapy Treatments

NEW YORK, Sept.  05, 2019  (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.

Genprex (GNPX) Featured in NetworkNewsWire Publication Summarizing Gene Therapy Treatment for Lung Cancer

NEW YORK, Aug.  23, 2019  (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of an audio press release broadcast titled, “Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector” and produced by NetworkNewsWire (“NNW”).

Genprex (GNPX) Featured in Broadcast Discussing Strength, Potential of Biotech Sector

NEW YORK, Aug.  22, 2019  (GLOBE NEWSWIRE) -- via NetworkWire -- Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.

Genprex (GNPX) Featured in NetworkNewsWire Publication Discussing Company’s Milestone Achievements

Atara Biotherapeutics

bluebird bio

Hemispherx Biopharma

Incyte

As our understanding of how cancer works evolves, so too are the methods that we are taking to treat the condition.

5 Immunotherapy Stocks to Keep a Close Eye On

News for Genprex Stock (GNPX)